Table 2.

Association of BMI in four cohorts of transgender men and women receiving gender affirming hormone therapy with age and duration of taking gender affirming hormone therapy (GAHT) using linear mixed model.

Model 1: Transgender women who entered the cohort after on GAHT for more than 6 months (N = 46)
Fixed Effects	Estimate	95%CI	P-value
Intercept	18.66	[14.91, 22.41]	<0.001
Age (years)	0.17	[0.08, 0.25]	<0.001
GAHT duration (quarters)	0.08	[−0.004, 0.16]	0.064

Model 2: Transgender women who entered the cohort prior to starting GAHT (N = 59)
Fixed Effects	Estimate	95%CI	P-value
Intercept	19.62	[16.24, 23.0]	<0.001
Age (years)	0.15	[0.05, 0.25]	0.004
GAHT duration (quarters)	0.13	[0.04, 0.21]	0.004

Model 3: Transgender men who entered the cohort after on GAHT for more than 6 months (N = 15)
Fixed Effects	Estimate	95%CI	P-value
Intercept	20.85	[13.5, 28.21]	<0.001
Age (years)	0.14	[−0.03, 0.31]	0.101
GAHT duration (quarters)	−0.020	[−1.28, 1.24]	0.739

Model 4: Transgender men who entered the cohort prior to starting GAHT (N = 25)
Fixed Effects	Estimate	95%CI	P-value
Intercept	19.62	[14.2, 25.05]	<0.001
Age (years)	0.16	[−0.03, 0.34]	0.093
GAHT duration (quarters)	−0.02	[-0.14,0.11]	0.790

P-value represent significance from log-transformed variables when relevant.